




Searching News Database: JAK1
HSMN NewsFeed - 14 Apr 2022
NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms
NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms
HSMN NewsFeed - 26 May 2020
Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer
Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer
HSMN NewsFeed - 16 Mar 2020
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
HSMN NewsFeed - 22 Aug 2018
Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance Momelotinib
Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance Momelotinib
HSMN NewsFeed - 9 Mar 2018
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
HSMN NewsFeed - 13 Jan 2016
Galapagos and Gilead Cleared by U.S. Federal Trade Commission to Close Global Partnership on Filgotinib
Galapagos and Gilead Cleared by U.S. Federal Trade Commission to Close Global Partnership on Filgotinib
HSMN NewsFeed - 15 Mar 2011
Incyte’s Ruxolitinib (INCB18424) Meets Primary Endpoint in Second Phase III Study
Incyte’s Ruxolitinib (INCB18424) Meets Primary Endpoint in Second Phase III Study
HSMN NewsFeed - 14 Oct 2010
YM Biosciences Appoints Dr. Nick Glover as Chief Executive Officer and Announces Annual Meeting
YM Biosciences Appoints Dr. Nick Glover as Chief Executive Officer and Announces Annual Meeting
Additional items found! 1

Members Archive contains
1 additional stories matching:
JAK1
(Password required)
JAK1
(Password required)